Okuno, Shota
Higo, Shuichiro
Kondo, Takumi
Shiba, Mikio
Kameda, Satoshi
Inoue, Hiroyuki
Tabata, Tomoka
Ogawa, Shou
Morishita, Yu
Sun, Congcong
Ishino, Saki
Honda, Tomoyuki
Miyagawa, Shigeru
Sakata, Yasushi
Funding for this research was provided by:
Japan Society for the Promotion of Science (21H02915, 23K15128, 21H02915)
Japan Agency for Medical Research and Development (22bm0804035h0001, 21bm0804008h0005, 22bm0804035h0001)
the SENSHIN Medical Research Foundation
Cross-Innovation Initiative established by Osaka University Graduate School of Medicine and Osaka University Hospital
the Japan Foundation for Applied Enzymology
Article History
Received: 14 August 2023
Accepted: 22 November 2023
First Online: 4 December 2023
Competing interests
: The Department of Medical Therapeutics for Heart Failure is currently a Joint Research Department with TOA EIYO Pharmaceutical Company. No other authors possess conflict of interest.